PuraMed BioScience Nears Completion of a Hemp-Derived-Cannabinoid-Based Non-Prescription Medication for Treatment of Epilepsy Symptoms

SCHOFIELD, Wis., Oct. 10, 2014 /PRNewswire/ -- PuraMed BioScience^®, Inc., (OTCPink: PMBSD), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it is nearing the completion of development of its new non-prescription, hemp-based, homeopathic medication for treatment of epilepsy symptoms including seizures and seizure-related headaches.

Both epilepsy and migraines appear to be triggered by the same coritcal spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many people who suffer from migraines are prescribed epilepsy medications.

The third most common neurological disorder in the US, epilepsy affects approximately 2.7 million people, with children and older adults being most susceptible. The condition also causes up to 50,000 sudden deaths each year.

Recent research has shown cannabidiol (CBD), one of the hemp-derived cannabinoids, to be an effective therapy in the treatment of epilepsy symptoms.

"By incorporating standardized hemp oil into our current patented, over-the-counter migraine relief formula, MigraPure, we believe we can offer relief to people who not only suffer with migraines, but also offer relief to people who have seizure-related headaches and other epilepsy-type symptoms," said Russ Mitchell, CEO, PuraMed BioScience. "Due to the close association between migraine headaches and epilepsy, the development of a hemp-based treatment for epilepsy symptoms is a logical step for the Company to make. Hemp-based cannabinoids combined with our experience in building herbal medicines that outperform traditional allopathic treatments fit extremely well with our unique delivery systems and our business philosophy."

About MigraPure Advanced Migraine Relief

MigraPure (clinically tested as LipiGesic M) is an advanced homeopathic feverfew and ginger gel formulation which has been shown to be highly effective in the treatment of migraine and migraine associated symptoms. MigraPure has an excellent safety profile and has no reported drug interactions. During the double-blind, placebo-controlled clinical trial, participants who suffered acute migraine experienced relief (mild to no pain) in 64 percent of migraine occurrences.

MigraPure (f/k/a LipiGesic M) was also selected as one of 16 formulations and the only over-the-counter medication cited in an article co-authored by Dr. Roger Cady entitled, Advances in Drug Development for Acute Migraine. MigraPure was the only product described by Dr. Cady as "an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options." The article was published in Drugs, a top-tier medical journal.

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products, which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts.

In addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience plans to launch additional hemp-based, cannabinoid-enhanced, anti-inflammatory and anxiolytic products as it moves forward in the development of its cannabinoid product line. www.PuramedBioScience.com

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
[email protected]

SOURCE PuraMed BioScience, Inc.